CD22 and precursor B-cell acute lymphoblastic leukemia: Despite these cases of relapsed disease, the presented clinical outcomes for this cohort of patients collectively demonstrate the profound clinical benefit of CD19/CD22 CAR T cell therapy in the setting of relapsed adult B-ALL, a highly aggressive and predominantly fatal condition [21, 22].